Our Website Uses Cookies
We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.
For more information, please contact us or consult our Privacy Notice.
Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
- Home
- News and Insights
- Insights
- Federal Circuit Delivers Two Important Decisions on Obviousness Type Double Patenting
Federal Circuit Delivers Two Important Decisions on Obviousness-Type Double Patenting
December 10, 2018, Covington Alert
On December 7, 2018, the Federal Circuit issued two highly-anticipated decisions clarifying the application of the obviousness-type double patenting doctrine: Novartis AG v. Ezra Ventures LLC (patent term extension ("PTE")), and Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical Inc. (pre-Uruguay Round Agreements Act ("URAA") versus post-URAA patents). In both cases, the Federal Circuit declined to extend the reasoning of Gilead Sciences Inc. v. Natco Pharma Ltd. to the factual scenarios presented.
April 2, 2019
WASHINGTON—Covington has chosen Washington partner Brianne Bharkhda to be a member of The Leadership Council on Legal Diversity’s 2019 class of Fellows. Ms. Bharkhda will participate in programs designed to identify, train, and advance the next generation of leaders in the legal profession. Ms. Bharkhda is a litigator who represents a variety of clients in ...
Fed. Circ. Reins In Reach Of Double-Patenting Doctrine
December 14, 2018, Law360
Brianne Bharkhda and Natalie Derzko are quoted in Law360 regarding two Federal Circuit decisions that have cleared up lingering questions about patents can be invalidated under the double-patenting doctrine and identified situations where it does not apply. Ms. Bharkhda says, "I would characterize the two decisions as further defining the contours of the ...
Covington Represents Underwriters in Cidara IPO
April 20, 2015
NEW YORK — Covington advised the underwriters in the $76.8 million initial public offering of common stock of Cidara Therapeutics, Inc. Shares of Cidara trade on the NASDAQ Global Market under the ticker “CDTX.” Cidara is a biopharmaceutical company focused on the discovery, development and commercialization of anti-infectives for treatment of diseases ...